Skip to main content
Premium Trial:

Request an Annual Quote

AIT, BioVendor, Scienion to Develop Colon Cancer Dx

NEW YORK (GenomeWeb) – The AIT Austrian Institute of Technology, BioVendor, and Scienion announced today a partnership to develop an in vitro diagnostic test for the early detection of colon cancer.

The collaboration will be based on AIT's proprietary autoantibody biomarkers for the early detection and screening of colon cancer from blood samples. BioVendor, through its subsidiary TestLine Clinical Diagnostics, is contributing its development expertise and distribution network. Scienion is providing expertise in the microarray market and will be responsible for assay development and manufacturing using its microtiter plates.

Financial and other terms of the agreement were not disclosed.

Scienion and BioVendor have an existing collaboration, and in a statement Scienion CEO Holger Eickhoff said, "Getting AIT with its proprietary biomarker panel on board as a third partner is the perfect match for the development of colon cancer IVD. Once established, our test kit has the potential for broad colon cancer screening applications."